Furthermore, XOR inhibition by topiroxostat reversed both increased plasma XOR activity and the progression of neointima formation in NASH model mice of the present study to similar levels observed in control mice independent of liver dysfunction (Figure 4, E and F). This evidence concerns the gene XDH and metabolic dysfunction-associated steatohepatitis.